-
A SENTENCE-LEVEL ASSESSMENT FRAMEWORK FOR EVALUATING AI-GENERATED STUDY SUMMARIES AGAINST EXPERT-CURATED CLINICAL OVERVIEW
Aug 11, 2026, 17:16 PM -
A PROOF-OF-CONCEPT FRAMEWORK FOR ADAPTING EQ-5D-5L UTILITY ESTIMATES FOR HEALTH TECHNOLOGY ASSESSMENT IN MENA: AN ASTHMA CASE STUDY
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ANALYSIS OF PERIOPERATIVE PEMBROLIZUMAB AND ENFORTUMAB VEDOTIN FOR THE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER PATIENTS WHO ARE INELIGIBLE FOR CISPLATIN-BASED CHEMOTHERAPY IN BELGIUM
Aug 11, 2026, 17:16 PM -
QUANTIFYING THE "INVISIBLE" BURDEN: ESTIMATING UNDIAGNOSED CARDIO-RENAL-METABOLIC CONDITIONS USING LINKED EMR-CLAIMS DATA
Aug 11, 2026, 17:16 PM -
PREPARING FOR JOINT CLINICAL ASSESSMENT: COMPARING HTA COMPARATORS, CLINICAL PRACTICE, AND REAL-WORLD FIRST-LINE NSCLC TREATMENT IN THE EU4 + UK
Aug 11, 2026, 17:16 PM -
LONG-TERM REDUCTION IN PATIENT-REPORTED BLOOD-IN-STOOL ENTRIES ON ADALIMUMAB IN ULCERATIVE COLITIS: REAL-WORLD EVIDENCE FROM THE AMPERSAND DIGITAL COHORT
Aug 11, 2026, 17:16 PM -
LOW ON AGENCY, HIGH ON BURNOUT: A NATIONAL CROSS-SECTIONAL STUDY AMONG PHARMACY ASSISTANTS AND TECHNICIANS DURING THE INITIAL STAGES OF THE NOVEL CORONAVIRUS (COVID-19) PANDEMIC IN HUNGARY
Aug 11, 2026, 17:16 PM -
ESTIMATING THE POTENTIAL COST SAVINGS OF GERIATRIC ASSESSMENT AND MANAGEMENT (GAM) FOR OLDER ADULTS RECEIVING SYSTEMIC CANCER THERAPY IN JAPAN: A SCENARIO-BASED ANALYSIS
Aug 11, 2026, 17:16 PM -
THE IMPACT OF CAREGIVING FOR PEOPLE WITH AUTOIMMUNE NEUROMUSCULAR DISORDERS (ANMD): A LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
THE TREAT-LATE EQUILIBRIUM IN CHRONIC KIDNEY DISEASE BEHAVIORAL ECONOMICS OF A $228 BILLION FISCAL BURDEN
Aug 11, 2026, 17:16 PM -
UNDERSTANDING DIETS FROM THE ROOTS: OPPORTUNITIES AND LIMITATIONS IN THE INFODEMIOLOGICAL ANALYSIS OF INFORMATION-SEEKING BEHAVIOR REGARDING MACRONUTRIENTS IN THE HUNGARIAN POPULATION
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN BEFORE AND AFTER SJOGREN'S DISEASE DIAGNOSIS IN THE US: A RETROSPECTIVE CLAIMS-BASED ANALYSIS
Aug 11, 2026, 17:16 PM -
PHARMACEUTICAL PAYBACK BURDEN AND HEALTH TECHNOLOGY ASSESSMENT (HTA) MATURITY ACROSS EU MEMBER STATES: A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
IMPACT OF THE NEW UK EQ-5D-5L VALUE SET ON HEALTH STATE UTILITY VALUES: A MULTI-COUNTRY COMPARISON ACROSS DISEASE GROUPS
Aug 11, 2026, 17:16 PM -
EPIDEMIOLOGY AND DISEASE BURDEN OF DERMATOMYOSITIS IN GERMANY - FIRST EXPERIENCES WITH THE HEALTH DATA LAB IN A NATIONWIDE RETROSPECTIVE CLAIMS DATA ANALYSIS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF OBINUTUZUMAB FOR THE TREATMENT OF ACTIVE LUPUS NEPHRITIS IN THE UK
Aug 11, 2026, 17:16 PM -
COMPARATIVE EVALUATION OF GRAPH RETRIEVAL-AUGMENTED GENERATION (GRAPHRAG) AND CONVENTIONAL RAG FOR EVIDENCE SYNTHESIS
Aug 11, 2026, 17:16 PM -
ANALYSIS OF TRANSPARENCY COMMISSION EVALUATIONS OF ADOLESCENT INDICATION EXTENSIONS IN RELATION TO CORRESPONDING ADULT EVALUATIONS IN FRANCE
Aug 11, 2026, 17:16 PM -
TREATMENT EFFECT WANING ASSUMPTIONS VERSUS LONG-TERM EVIDENCE FOR IMMUNE CHECKPOINT INHIBITORS IN NICE'S SINGLE TECHNOLOGY APPRAISALS
Aug 11, 2026, 17:16 PM -
AN 8-POINT WORSENING AND A 10-POINT IMPROVEMENT ON THE MULTIPLE-SCLEROSIS IMPACT SCALE 29-ITEM (MSIS-29) V2 ARE CLINICALLY MEANINGFUL
Aug 11, 2026, 17:16 PM
